Loading organizations...
Loading organizations...
Huichuang Medical: Develops NIR imaging technology, including fNIRS, for brain disease diagnosis and mental health research.
Huichuang Medical, based in Danyang, Jiangsu Province, China, develops near-infrared (NIR) imaging and evaluation technology, including functional near-infrared spectroscopy (fNIRS) for high-resolution brain imaging. Their flagship product, NirScan, is the world's first NMPA-approved device with over 100 channels, enabling whole-brain imaging for clinical diagnosis of brain diseases and mental health conditions. The company's equipment is deployed in over 60 grade A hospitals and research units across China. Huichuang Medical raised ￥10 million in Series A funding in September 2020, led by Qingyuan Investment, which also participated in their Pre-A round. The organization was founded in 2016 by Wang Daifa, who serves as chairman and chief scientist, with Fu Qijun as R&D director, and recently achieved a breakthrough in fNIRS imaging technology recognized in national media in February 2024.
Huichuang Medical has raised $27.5M across 2 funding rounds.
Huichuang Medical has raised $27.5M in total across 2 funding rounds.
Huichuang Medical has raised $27.5M in total across 2 funding rounds.
Huichuang Medical has raised $27.5M across 2 funding rounds. Most recently, it raised $13.8M Series B in May 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 31, 2024 | $13.8M Series B | ||
| Oct 31, 2023 | $13.7M Series B |